Full Press Release Details
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy.
BIIB
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Key Takeaway: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy